BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Sanofi (France) (SAN.PA) Diabetes Drug Wins EU Panel Recommendation


11/20/2012 7:10:11 AM

Sanofi has received a recommendation for European approval of once-daily Lyxumia for the treatment of adults with type 2 diabetes mellitus. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has endorsed the therapy to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin, in cases when these, together with diet and exercise, have proven ineffective on their own. Data from the GetGoal phase III programme has demonstrated the efficacy, safety and tolerability profile of the drug among more than 5,000 test subjects. Sanofi now expects to receive final European approval of lixisenatide within two or three months, while a US regulatory submission is also planned next month.

Read at News Release
Read at Bloomberg

   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->